Moleculin Biotech is a clinical stage pharmaceutical company dedicated to tackling highly resistant cancers and viruses. With strong partnerships with renowned research organizations, their goal is to develop innovative treatments that can truly make a difference in people's lives. Their leading program, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance mechanisms while minimizing cardiotoxicity.

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. In addition, Moleculin Biotech is working on WP1066 and WP1220, both with immune and transcription modulation properties. These candidates aim to inhibit oncogenic transcription factors, stimulate the immune response, and target diseases such as brain tumors, pancreatic cancer, and other cancers.

Furthermore, they are developing antimetabolite drugs like WP1122, with potential applications in treating COVID-19 and other viral infections, as well as various cancer indications including brain tumors and pancreatic cancer. Moleculin Biotech is committed to pushing the boundaries of medical innovation and finding effective solutions for challenging diseases